A new class of synthetic anti-lipopolysaccharide peptides inhibits influenza A virus replication by blocking cellular attachment

Antiviral Research

Volumn 104, Issue 1, 2014, Pages 23-33

  Hoffmann, Julia ^a   Schneider, Carola ^a   Heinbockel, Lena ^b   Brandenburg, Klaus ^b   Reimer, Rudolph ^a   Gabriel, Gülsah ^a  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Cellular attachment inhibitor; Influenza virus; Mouse model; Synthetic anti lipopolysaccharide peptides (SALPs)

Indexed keywords

CELLULAR ATTACHMENT INHIBITOR; INFLUENZA VIRUS; MOUSE MODEL; SYNTHETIC ANTI-LIPOPOLYSACCHARIDE PEPTIDES (SALPS);

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DISEASE MODELS, ANIMAL; HEMAGGLUTINATION; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H7N7 SUBTYPE; KINETICS; LIPOPOLYSACCHARIDES; MICE; N-ACETYLNEURAMINIC ACID; ORTHOMYXOVIRIDAE INFECTIONS; PEPTIDES; PROTEIN BINDING; RECEPTORS, VIRUS; VIRUS ATTACHMENT; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84893821628     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.01.015     Document Type: Article

References (42)

1. T. Baranovich, R.G. Webster, and E.A. Govorkova Fitness of neuraminidase inhibitor-resistant influenza A viruses Curr. Opin. Virol. 1 2011 574 581
2. J. Beigel, and M. Bray Current and future antiviral therapy of severe seasonal and avian influenza Antiviral Res. 78 2008 91 102
3. R.A. Bright, D.K. Shay, B. Shu, N.J. Cox, and A.I. Klimov Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States JAMA 295 2006 891 894
4. CDC, 2009. < http://www.cdc.gov/flu/weekly/weeklyarchives2008-2009/ weekly15.htm >.
5. E.D. Clercq Highlights in antiviral drug research: antivirals at the horizon Med. Res. Rev. 2012
6. W.L. Davies, R.R. Grunert, R.F. Haff, J.W. McGahen, E.M. Neumayer, M. Paulshock, J.C. Watts, T.R. Wood, E.C. Hermann, and C.E. Hoffmann Antiviral activity of 1-Adamantanamine (amantadine) Science 144 1964 862 863
7. E. De Clercq Antiviral agents active against influenza A viruses Nat. Rev. Drug Discov. 5 2006 1015 1025 (Pubitemid 44835128)
8. V.M. Deyde, X. Xu, R.A. Bright, M. Shaw, C.B. Smith, Y. Zhang, Y. Shu, L.V. Gubareva, N.J. Cox, and A.I. Klimov Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide J. Infect. Dis. 196 2007 249 257 (Pubitemid 47047464)
9. N.J. Dharan, L.V. Gubareva, J.J. Meyer, M. Okomo-Adhiambo, R.C. McClinton, S.A. Marshall, K. St George, S. Epperson, L. Brammer, A.I. Klimov, J.S. Bresee, and A.M. Fry Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States JAMA 301 2009 1034 1041
10. K. Droebner, S. Pleschka, S. Ludwig, and O. Planz Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo Antiviral Res. 92 2011 195 203
11. K.M. ElSawy, R. Twarock, C.S. Verma, and L.S. Caves Peptide inhibitors of viral assembly: a novel route to broad-spectrum antivirals J. Chem. Inf. Model. 52 2012 770 776
12. A.E. Fiore, A. Fry, D. Shay, L. Gubareva, J.S. Bresee, and T.M. Uyeki Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the advisory committee on immunization Practices (ACIP) MMWR Recomm. Rep. 60 2011 1 24
13. J.L. Fox Antivirals become a broader enterprise Nat. Biotechnol. 25 2007 1395 1402 (Pubitemid 350233129)
14. G. Gabriel, B. Dauber, T. Wolff, O. Planz, H.D. Klenk, and J. Stech The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host Proc. Natl. Acad. Sci. USA 102 2005 18590 18595 (Pubitemid 43011270)
15. G. Gabriel, H. Garn, M. Wegmann, H. Renz, A. Herwig, H.D. Klenk, and J. Stech The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine Vaccine 26 2008 956 965
16. G. Gabriel, K. Klingel, A. Otte, S. Thiele, B. Hudjetz, G. Arman-Kalcek, M. Sauter, T. Shmidt, F. Rother, S. Baumgarte, B. Keiner, E. Hartmann, M. Bader, G.G. Brownlee, E. Fodor, and H.D. Klenk Differential use of importin-alpha isoforms governs cell tropism and host adaptation of influenza virus Nat. Commun. 2 2011 156
17. R. Gao, B. Cao, Y. Hu, Z. Feng, D. Wang, W. Hu, J. Chen, Z. Jie, H. Qiu, K. Xu, X. Xu, H. Lu, W. Zhu, Z. Gao, N. Xiang, Y. Shen, Z. He, Y. Gu, Z. Zhang, Y. Yang, X. Zhao, L. Zhou, X. Li, S. Zou, Y. Zhang, L. Yang, J. Guo, J. Dong, Q. Li, L. Dong, Y. Zhu, T. Bai, S. Wang, P. Hao, W. Yang, J. Han, H. Yu, D. Li, G.F. Gao, G. Wu, Y. Wang, Z. Yuan, and Y. Shu Human infection with a novel avian-origin influenza A (H7N9) virus N. Engl. J. Med. 368 2013 1888 1897
18. T. Gutsmann, I. Razquin-Olazaran, I. Kowalski, Y. Kaconis, J. Howe, R. Bartels, M. Hornef, T. Schurholz, M. Rossle, S. Sanchez-Gomez, I. Moriyon, G. Martinez de Tejada, and K. Brandenburg New antiseptic peptides to protect against endotoxin-mediated shock Antimicrob. Agents Chemother. 54 2010 3817 3824
19. F.G. Hayden, and M.D. de Jong Emerging influenza antiviral resistance threats J. Infect. Dis. 203 2011 6 10
20. L. Heinbockel, S. Sanchez-Gomez, G. Martinez de Tejada, S. Domming, J. Brandenburg, Y. Kaconis, M. Hornef, A. Dupont, S. Marwitz, T. Goldmann, M. Ernst, T. Gutsmann, T. Schurholz, and K. Brandenburg Preclinical investigations reveal the broad-spectrum neutralizing activity of peptide pep 19-2.5 on bacterial pathogenicity factors Antimicrob. Agents Chemother. 57 2013 1480 1487
21. B. Hudjetz, and G. Gabriel Human-like PB2 627K influenza virus polymerase activity is regulated by importin-alpha1 and -alpha7 PLoS Pathog. 8 2012 e1002488
22. A. Huther, and U. Dietrich The emergence of peptides as therapeutic drugs for the inhibition of HIV-1 AIDS Rev. 9 2007 208 217 (Pubitemid 351181619)
23. Y. Kaconis, I. Kowalski, J. Howe, A. Brauser, W. Richter, I. Razquin-Olazaran, M. Inigo-Pestana, P. Garidel, M. Rossle, G. Martinez de Tejada, T. Gutsmann, and K. Brandenburg Biophysical mechanisms of endotoxin neutralization by cationic amphiphilic peptides Biophys. J. 100 2011 2652 2661
24. S.M. Kang, J.M. Song, and R.W. Compans Novel vaccines against influenza viruses Virus Res. 162 2011 31 38
25. C.U. Kim, W. Lew, M.A. Williams, H. Liu, L. Zhang, S. Swaminathan, N. Bischofberger, M.S. Chen, D.B. Mendel, C.Y. Tai, W.G. Laver, and R.C. Stevens Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity J. Am. Chem. Soc. 119 1997 681 690 (Pubitemid 27101232)
26. H.D. Klenk, W. Garten, and M. Matrosovich Molecular mechanisms of interspecies transmission and pathogenicity of influenza viruses: lessons from the 2009 pandemic Bioessays 2011
27. M. Krepstakies, J. Lucifora, C.H. Nagel, M.B. Zeisel, B. Holstermann, H. Hohenberg, I. Kowalski, T. Gutsmann, T.F. Baumert, K. Brandenburg, J. Hauber, and U. Protzer A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses J. Infect. Dis. 205 2012 1654 1664
28. D.S. Miller, J. Finnie, T.R. Bowden, A.C. Scholz, S. Oh, T. Kok, C.J. Burrell, L. Trinidad, D.B. Boyle, and P. Li Preclinical efficacy studies of influenza A haemagglutinin precursor cleavage loop peptides as a potential vaccine J. Gen. Virol. 92 2011 1152 1161
29. MMWR, 2012. Update: Influenza Activity - United States, 2011-12 Season and Composition of the 2012-13 Influenza Vaccine, vol. 61, pp. 414-420.
30. A. Moscona Neuraminidase inhibitors for influenza N. Engl. J. Med. 353 2005 1363 1373 (Pubitemid 41362704)
31. A. Moscona Global transmission of oseltamivir-resistant influenza N. Engl. J. Med. 360 2009 953 956
32. J.M. Nicholls, R.B. Moss, and S.M. Haslam The use of sialidase therapy for respiratory viral infections Antiviral Res. 98 2013 401 409
33. A. Otte, M. Sauter, L. Alleva, S. Baumgarte, K. Klingel, and G. Gabriel Differential host determinants contribute to the pathogenesis of 2009 pandemic H1N1 and human H5N1 influenza A viruses in experimental mouse models Am. J. Pathol. 179 2011 230 239
34. J.R. Schnell, and J.J. Chou Structure and mechanism of the M2 proton channel of influenza A virus Nature 451 2008 591 595 (Pubitemid 351186272)
35. T. Schuerholz, K. Brandenburg, and G. Marx Antimicrobial peptides and their potential application in inflammation and sepsis Crit. Care 16 2012 207
36. D.F. Smee, B.L. Hurst, M.H. Wong, K.W. Bailey, E.B. Tarbet, J.D. Morrey, and Y. Furuta Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice Antimicrob. Agents Chemother. 54 2010 126 133
37. J. Stevens, O. Blixt, L. Glaser, J.K. Taubenberger, P. Palese, J.C. Paulson, and I.A. Wilson Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities J. Mol. Biol. 355 2006 1143 1155 (Pubitemid 43012153)
38. R. Takano, M. Kiso, M. Igarashi, Q.M. Le, M. Sekijima, K. Ito, A. Takada, and Y. Kawaoka Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the neuraminidase of subtype H5N1 avian influenza A viruses J. Infect. Dis. 207 2013 89 97
39. C.W. Tan, Y.F. Chan, K.M. Sim, E.L. Tan, and C.L. Poh Inhibition of enterovirus 71 (EV-71) infections by a novel antiviral peptide derived from EV-71 capsid protein VP1 PLoS ONE 7 2012 e34589
40. M. von Itzstein, W.Y. Wu, G.B. Kok, M.S. Pegg, J.C. Dyason, B. Jin, T. Van Phan, M.L. Smythe, H.F. White, and S.W. Oliver et al. Rational design of potent sialidase-based inhibitors of influenza virus replication Nature 363 1993 418 423 (Pubitemid 23179386)
41. WHO, 2009. < http://www.who.int/mediacentre/factsheets/fs211/en/index. html >.
42. WHO, 2012. < http://www.who.int/influenza/human-animal-interface/EN- GIP-20120810CumulativeNumberH5N1cases.pdf >.